Atlas Trials

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT04665765 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04665765
Sponsor
City of Hope Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-Cell Lymphoma UnclassifiableRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
Start date
2021-01-18
Primary completion
2022-07-26
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.